Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Radical -xh acid – or anhydride – acid halide or salt thereof...
Reexamination Certificate
2004-01-21
2004-12-28
Killos, Paul J. (Department: 1625)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Radical -xh acid, or anhydride, acid halide or salt thereof...
C562S500000
Reexamination Certificate
active
06835751
ABSTRACT:
BACKGROUND OF THE INVENTION
Compounds of formula
wherein R
1
is hydrogen or a lower alkyl radical and n is 4, 5, or 6 are known in U.S. Pat. No. 4,024,175 and its divisional U.S. Pat. No. 4,087,544. The uses disclosed are: protective effect against cramp induced by thiosemicarbazide; protective action against cardiazole cramp; the cerebral diseases, epilepsy, faintness attacks, hypokinesia, and cranial traumas; and improvement in cerebral functions. The compounds are useful in geriatric patients. The patents are hereby incorporated by reference.
SUMMARY OF THE INVENTION
The instant invention is a series of novel bicyclic amino acids, their pharmaceutically acceptable salts, and the prodrugs of the amino acids.
The compounds are those of formula:
wherein n is an integer of from 1 to 4, where there are stereocenters, each center may be independently R or S.
Preferred compounds of the invention are those of Formulae I-IV above wherein n is an integer of from 2 to 4.
Other preferred compounds are those of Formula I above.
Especially preferred compounds are:
(1&agr;,6&agr;,8&bgr;)(2-Aminomethyl-octahydro-inden-2-yl)-acetic acid;
(2-Aminomethyl-octahydro-inden-2-yl)-acetic acid;
(2-Aminomethyl-octahydro-pentalen-2-y)-acetic acid;
(2-Aminomethyl-octahydro-pentalen-2-yl)-acetic acid;
(3-Aminomethyl-bicyclo[3.2.0]hept-3-yl)-acetic acid;
(3-Aminomethyl-bicyclo[3.2.0]hept-3-yl)-acetic acid; and
(2-Aminomethyl-octahydro-inden-2-yl)-acetic acid.
Other preferred compounds are those selected from
(1&agr;,5&bgr;)(3-Aminomethyl-bicyclo[3.1.0]hex-3-yl)-acetic acid,
(1&agr;,5&bgr;)(3-Aminomethyl-bicyclo[3.2.0]hept-3-yl)-acetic acid,
(1&agr;,5&bgr;)(2-Aminomethyl-octahydro-pentalen-2-yl)-acetic acid,
(1&agr;,6&bgr;)(2-Aminomethyl-octahydro-inden-2-yl)-acetic acid,
(1&agr;,7&bgr;)(2-Aminomethyl-decahydro-azulen-2-yl)-acetic acid,
(1&agr;,5&bgr;)(3-Aminomethyl-bicyclo[3.1.0]hex-3-yl)-acetic acid,
(1&agr;,5&bgr;)(3-Aminomethyl-bicyclo[3.2.0]hept-3-yl)-acetic acid,
(1&agr;,5&bgr;)(2-Aminomethyl-octahydro-pentalen-2-yl)-acetic acid,
(1&agr;,6&bgr;)(2-Aminomethyl-octahydro-inden-2-yl)-acetic acid,
(1&agr;,7&bgr;)(2-Aminomethyl-decahydro-azulen-2-yl)-acetic acid,
(1&agr;,3&bgr;,5&agr;)(3-Aminomethyl-bicyclo[3.1.0]hex-3-yl)-acetic acid,
(1&agr;,3&agr;,5&agr;)(3-Aminomethyl-bicyclo[3.2.0]hept-3-yl)-acetic acid,
(1&agr;,3&agr;,5&agr;)2-Aminomethyl-octahydro-pentalen-2-yl)-acetic acid,
(1&agr;,6&agr;,8&agr;)(2-Aminomethyl-octahydro-inden-2-yl)-acetic acid,
(1&agr;,7&agr;,9&agr;)(2-Aminomethyl-decahydro-azulen-2-yl)-acetic acid,
(1&agr;,3&bgr;,5&agr;)(3-Aminomethyl-bicyclo[3.1.0]hex-3-yl)-acetic acid,
(1&agr;,3&bgr;,5&agr;)(3-Aminomethyl-bicyclo[3.2.0]hept-3-yl)-acetic acid,
(1&agr;,3&bgr;,5&agr;)(2-Aminomethyl-octahydro-pentalen-2-yl)-acetic acid,
(1&agr;,6&agr;,8&bgr;)(2-Aminomethyl-octahydro-inden-2-yl)-acetic acid,
(1&agr;,7&agr;,9&bgr;)(2-Aminomethyl-decahydro-azulen-2-yl)-acetic acid,
((1R,3R,6R)-3-Aminomethyl-bicyclo[4.1.0]hept-3-yl)-acetic acid,
((1R,3 S,6R)-3-Aminomethyl-bicyclo[4.1.0]hept-3-yl)-acetic acid,
((1S,3S,6S)-3-Aminomethyl-bicyclo[4.1.0]hept-3-yl)-acetic acid,
((1S,3R,6S)-3-Aminomethyl-bicyclo[4.1.0]hept-3-yl)-acetic acid,
((1R,3R,6S)-3-Aminomethyl-bicyclo[4.2.0]oct-3-yl)-acetic acid,
((1R,3 S,6S)-3-Aminomethyl-bicyclo[4.2.0]oct-3-yl)-acetic acid,
((1S,3S,6R)-3-Aminomethyl-bicyclo[4.2.0]oct-3-yl)-acetic acid,
((1S,3R,6R)-3-Aminomethyl-bicyclo[4.2.0]oct-3-yl)-acetic acid,
((3&agr;R,5R,7&agr;S)-5-Aminomethyl-octahydro-inden-5-yl)-acetic acid,
((3&agr;R,5S,7&agr;S)-5-Aminomethyl-octahydro-inden-5-yl)-acetic acid,
((3&agr;S,5S,7&agr;R)-5-Aminomethyl-octahydro-inden-5-yl)-acetic acid,
((3&agr;S,5R,7&agr;R)-5-Aminomethyl-octahydro-inden-5-yl)-acetic acid,
((2R,4&agr;S,8&agr;R)-2-Aminomethyl-decahydro-naphthalen-2-yl)-acetic acid,
((2S,4&agr;S,8&agr;R)-2-Aminomethyl-decahydro-naphthalen-2-yl)-acetic acid,
((2S,4&agr;R,8&agr;S)-2-Aminomethyl-decahydro-naphthalen-2-yl)-acetic acid,
((2R,4&agr;S,8&agr;S)-2-Aminomethyl-decahydro-naphthalen-2-yl)-acetic acid,
((2R,4&agr;S,9&agr;R)-2-Aminomethyl-decahydro-benzocyclophepten-2-yl)-acetic acid,
((2S,4&agr;S,9&agr;R)-2-Aminomethyl-decahydro-benzocyclophepten-2-yl)-acetic acid,
((2S,4&agr;R,9&agr;S)-2-Aminomethyl-decahydro-benzocyclophepten-2-yl)-acetic acid,
((2R,4&agr;R,9&agr;S)-2-Aminomethyl-decahydro-benzocyclophepten-2-yl)-acetic acid,
((1R,3R,6S)-3-Aminomethyl-bicyclo[4.1.0]hept-3-yl)-acetic acid,
((1R,3S,6S)-3-Aminomethyl-bicyclo[4.1.0]hept-3-yl)-acetic acid,
((1S,3S,6R)-3-Aminomethyl-bicyclo[4.1.0]hept-3-yl)-acetic acid,
((1S,3R,6R)-3-Aminomethyl-bicyclo[4.1.0]hept-3-yl)-acetic acid,
((1R,3R,6R)3-Aminomethyl-bicyclo[4.2.0]oct-3-yl)-acetic acid,
((1R,3S,6R)-3-Aminomethyl-bicyclo[4.2.0]oct-3-yl)-acetic acid,
((1S,3S,6S)-3-Aminomethyl-bicyclo[4.2.0]oct-3-yl)-acetic acid,
((1S,3R,6S)-3-Aminomethyl-bicyclo[4.2.0]oct-3-yl)-acetic acid,
((3&agr;R,5R,7&agr;R)-5-Aminomethyl-octahydro-inden-5-yl)-acetic acid,
((3&agr;R,5S,7&agr;R)-5-Aminomethyl-octahydro-inden-5-yl)-acetic acid,
((3&agr;S,5S,7&agr;S)-5-Aminomethyl-octahydro-inden-5-yl)-acetic acid,
((3&agr;S,5R,7&agr;S)-5-Aminomethyl-octahydro-inden-5-yl)-acetic acid,
((2R,4&agr;R,8&agr;R)-2-Aminomethyl-decahydro-naphthalen-2-yl)-acetic acid,
((2S,4&agr;S,8&agr;R)-2-Aminomethyl-decahydro-naphthalen-2-yl)-acetic acid,
((2S,4&agr;R,8&agr;S)-2-Aminomethyl-decahydro-naphthalen-2-yl)-acetic acid,
((2R,4&agr;S,8&agr;S)-2-Aminomethyl-decahydro-naphthalen-2-yl)-acetic acid,
((2R,4&agr;R,9&agr;R)-2-Aminomethyl-decahydro-benzocyclophepten-2-yl)-acetic acid,
((2S,4&agr;R,9&agr;R)-2-Aminomethyl-decahydro-benzocyclophepten-2-yl)-acetic acid,
((2S,4&agr;S,9&agr;S)-2-Aminomethyl-decahydro-benzocyclophepten-2-yl)-acetic acid, and
((2R,4&agr;S,9&agr;S)-2-Aminomethyl-decahydro-benzocyclophepten-2-yl)-acetic acid.
The compounds of the invention are useful in treating a variety of disorders. The disorders include: epilepsy, faintness attacks, hypokinesia, cranial disorders, neurodegenerative disorders, depression, anxiety, panic, pain, neuropathological disorders, and sleep disorders.
Intermediates useful in the preparation of the final products are also included in the scope of the invention.
REFERENCES:
patent: 2052979 (1970-06-01), None
patent: 2294697 (1975-12-01), None
patent: 9921824 (1909-05-01), None
Blakemore David Clive
Bryans Justin Stephen
Osborne Simon Andrew
Receveur Jean-Marie
Ashbrook Charles W.
Killos Paul J.
Kurlandsky David R.
Warner-Dambert Company LLC
LandOfFree
Bicyclic amino acids as pharmaceutical agents does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Bicyclic amino acids as pharmaceutical agents, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Bicyclic amino acids as pharmaceutical agents will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3294430